Table 1 Main characteristics of 127 patients treated with pegylated interferon-α (pegIFN).
Number of unique patients | 127 |
|---|---|
Total number of pegIFN LOT | 161 |
Sex, n (%) | |
Female | 85 (67%) |
Male | 42 (33%) |
Median age at diagnosis, years (min, max) | 37.0 (8.2, 77.4) |
IPSET-thrombosis score, % | |
Low | 37 |
Intermediate | 31 |
High | 30 |
Unknown | 2 |
Driver mutation, % | |
JAK2 V617F | 51 |
CALR Ex9 | 32 |
JAK2 V617F and CALR Ex9 | 2 |
MPL W515 | 5 |
Triple negative | 10 |
Splenomegaly, % | |
Yes | 29 |
No | 68 |
Unknown | 3 |
Smoking during pegIFN treatment, % | |
Yes | 11 |
No | 72 |
Unknown | 17 |
Median WBC, G/l (min, max)a | 8.2 (3.0, 17.3) |
Median PLT count, G/l (min, max)a | 780 (124, 2776) |
Median time until pegIFN start, years (min, max) | 1.9 (0.0, 32.7) |
Median total pegIFN treatment duration per patient, years (min, max) | 2.3 (0.1, 18.1) |
Reason for pegIFN start, % | |
Platelet count | 39 |
Prior thrombosis | 31 |
Symptoms | 9 |
Age >60 years | 7 |
Pregnancy | 7 |
Unknown | 7 |
Prior cytoreductive therapies, % | |
Hydroxyurea only | 20 |
Anagrelide only | 9 |
Hydroxyurea and anagrelide | 11 |
Busulfan | 1 |
None | 59 |
Response according to Barosi 2009 criteria, % | |
Complete response | 54 |
Partial response | 35 |
No response | 9 |
Unknown | 2 |
Vascular events per patient-year, % | |
Arterial | 0.64 |
Venous | 1.07 |
Progression to SMF per patient-year, % | 0.21 |
Leukemic transformation per patient-year, % | 0.00 |
Adverse events, % LOT | |
Flu-like symptoms | 41 |
Abnormal liver values | 16 |
Depression | 14 |
